IL2 and neoplasm: High-dose IL-2 presumably mediates anti-tumor activity through expansion of the CD8+ T cell and NK cell compartments, but it is also known to expand regulatory CD4+ FoxP3+ T cells (Tregs), which can mediate immune suppression and promote peripheral tolerance [15,16].